Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2331074 Target Snapshot

Adrenergic receptor · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
4Compounds
5Assays
0Approved Drugs
2.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Adrenergic receptor shows approved-linked disease relevance led by hypotension. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P35348. Start with hypotension, then reuse UniProt P35348 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hypotension, then reuse UniProt P35348 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 4 linked drugs
Open source guide
Disease program
hypotension

Adrenergic receptor shows approved-linked disease relevance led by hypotension. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with hypotension because it currently carries approved-linked support. Linked drugs include DROXIDOPA, EPHEDRINE HYDROCHLORIDE, EPHEDRINE SULFATE, EPINEPHRINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Adrenergic receptor as ChEMBL target CHEMBL2331074, mapped to UniProt P35348. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Adrenergic receptor
PROTEIN FAMILY · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2331074
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P35348
Alpha-1A adrenergic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Adrenergic receptor is the right protein anchor across sources, using UniProt P35348 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hypotension is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameAdrenergic receptor
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtP35348
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAlpha-1A adrenergic receptor
UniProt AccessionP35348
Component TypeProtein
Sequence Length466 aa

Alpha-1A adrenergic receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Adrenergic receptor, mapped to UniProt P35348. ChEMBL maps the protein component as Alpha-1A adrenergic receptor. Sequence length is 466 aa.

Mapped IDP35348
Review nameAdrenergic receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Adrenergic receptor shows approved-linked disease relevance led by hypotension. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
hypotension
4 linked drugs · 4 direct · 4 efficacy
Linked drugDROXIDOPA
Linked drugEPHEDRINE HYDROCHLORIDE
Linked drugEPHEDRINE SULFATE
Linked drugEPINEPHRINE
Approved-linked Approved
asthma
3 linked drugs · 3 direct · 3 efficacy
Linked drugEPHEDRINE HYDROCHLORIDE
Linked drugEPHEDRINE SULFATE
Linked drugEPINEPHRINE
Approved-linked Approved
cardiovascular disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugDROXIDOPA
Linked drugEPINEPHRINE
Approved-linked Approved
Nasal congestion
2 linked drugs · 2 direct · 2 efficacy
Linked drugEPHEDRINE HYDROCHLORIDE
Linked drugEPINEPHRINE
Approved-linked Approved
pain
2 linked drugs · 2 direct · 2 efficacy
Linked drugEPINEPHRINE
Linked drugEPINEPHRINE BITARTRATE
Approved-linked Approved
seasonal allergic rhinitis
2 linked drugs · 2 direct · 2 efficacy
Linked drugEPHEDRINE HYDROCHLORIDE
Linked drugEPINEPHRINE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with hypotension because it currently carries approved-linked support. Linked drugs include DROXIDOPA, EPHEDRINE HYDROCHLORIDE, EPHEDRINE SULFATE, EPINEPHRINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehypotension
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

EC502.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5278539 8.0 EC50 10.0 Preclinical
CHEMBL1204876 5.94 EC50 1150.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
1
5.5
0
6.0
0
6.5
0
7.0
0
7.5
1
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

5
Total Assays
2
Tested Compounds
2
Assay Types
Binding — 3 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 2 7.0
protein format 1 0 —
Functional — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine